Chinook Therapeutics is developing precision medicines for rare, severe chronic kidney diseases. Chronic kidney diseases are a growing worldwide problem with ineffective treatments and often lead to high medical costs, dialysis or transplantation. Chinook is capitalizing on the new understanding of kidney disease biology to discover and develop new precision medicines. For example, Chinook’s lead candidate, atrasentan, targets and blocks the endothelin A receptor and is currently being tested in a phase 3 clinical trial. By further exploring the latest biological insights from single cell RNA sequencing of patient kidney samples, Chinook seeks to build their therapeutic pipeline to target more kidney disease pathways.

Chinook Therapeutics

Short description:

Drug notes:

Long description:

Jobs: